Alpha Tau receives FDA approved IDE application to initiate study of Alpha DaRT

Alpha Tau (DRTS) Medical announced that the FDA has approved an Investigational Device Exemption, IDE, application to initiate a pilot study for the treatment of patients with locally recurrent prostate cancer using the Company’s Alpha DaRT technology. “We are excited to bring the Alpha DaRT technology to prostate cancer patients in the U.S.,” said Dr. Robert Den, Alpha Tau Chief Medical Officer. “According to the National Cancer Institute, over 300,000 new cases of prostate cancer will be diagnosed in 2025, and clinical literature indicates that up to 15% of patients treated with external beam radiation therapy can develop local recurrence within 15 years of treatment. We look forward to exploring Alpha DaRT as a new local salvage therapy for patients with recurrent prostate cancer, as an alternative to systemic androgen deprivation therapy.”